[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649318":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Istanbul Saglik Bilimleri University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: DPN+",null,"Patients diagnosed with Type 2 Diabetes Mellitus and diabetic polyneuropathy confirmed by clinical and electrophysiological evaluation.",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2: DPN-","Patients diagnosed with Type 2 Diabetes Mellitus without evidence of diabetic polyneuropathy.",{"label":16,"type":10,"description":17,"interventionNames":10},"Group 3: Healthy Control","Participants without diabetes mellitus or neuropathy.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"gülden ANATACA","CONTACT","+905059284244","ganataca@yahoo.com",[25],{"facility":26,"status":10,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Kanuni Sultan Süleyman Training and Research Hospital","Istanbul","Turkey (Türkiye)",{"type":30,"coordinates":31},"Point",[32,33],28.94966,41.01384,{"lat":33,"lon":32},[36],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","GÜLDEN ANATACA","Assistant Professor","100649318","is-serum-irisin-level-a-biomarker-in-diabetic-polyneuropathy-100649318",false,"NCT07734597","Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?","Evaluation of Serum Irisin Levels as a Potential Biomarker in Patients With Diabetic Polyneuropathy: A Single-center Prospective Cross-sectional Observational Study","Inclusion Criteria:\n\n* Age between 30 and 75 years\n* Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)\n* Ability to understand and sign informed consent\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)\n* Chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²)\n* Active infection\n* Myopathies or other muscle diseases\n* Central nervous system diseases (e.g., stroke, Parkinson disease)\n* Severe orthopedic conditions impairing mobility\n* Inability or unwillingness to provide informed consent",true,"ALL","30 Years","75 Years",{"count":53,"type":54},81,"ESTIMATED","12 Weeks","OBSERVATIONAL","Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.",[59,60,61],"Polyneuropathies","Diabetic Complications Neurological","Diabetes Mellitus Type 2",[63,64,65,66],"Biomarker","Type 2 Diabetes Mellitus","Diabetic polyneuropathies","Serum Irisin","NOT_YET_RECRUITING","2026-07-27",{"date":70,"type":71},"2026-07-29","ACTUAL",{"date":73,"type":54},"2026-07-30",{"date":75,"type":54},"2026-09-30",{"name":39,"class":6},1]